Loading…
Kalaris Therapeutics, Inc. is projected to decline to $3.25 by 2027, a -7% move from its current price of $3.51. KLRS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $3.39 | $3.51 | $3.64 | +0.06% |
| Aug 6 | $3.35 | $3.51 | $3.69 | +0.11% |
| Aug 7 | $3.31 | $3.52 | $3.73 | +0.17% |
| Aug 8 | $3.28 | $3.52 | $3.77 | +0.22% |
| Aug 9 | $3.26 | $3.52 | $3.80 | +0.28% |
| Aug 10 | $3.24 | $3.52 | $3.83 | +0.34% |
| Aug 11 | $3.22 | $3.52 | $3.86 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.22 | $3.52 | $3.86 | +0.39% |
| Week 2 | $3.11 | $3.54 | $4.03 | +0.79% |
| Week 3 | $3.03 | $3.55 | $4.16 | +1.19% |
| Week 4 | $2.97 | $3.57 | $4.28 | +1.58% |
| Week 5 | $2.92 | $3.58 | $4.39 | +1.99% |
| Week 6 | $2.87 | $3.59 | $4.49 | +2.39% |
| Week 7 | $2.83 | $3.61 | $4.59 | +2.79% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-VEGF drug for the treatment of neovascular age-related macular degeneration (nAMD) and other exudative retinal diseases.
The company was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. Founded in 2019 and headquartered in Berkeley Heights, New Jersey, the firm operates in the Healthcare sector.
KLRS is the ticker for Kalaris Therapeutics, Inc., currently trading at $3.58. The market capitalization stands at $85.18M and the stock ranks 4093 by market cap. These figures place the company as a smaller-cap, niche biotech player with a clinical-stage development program in retinal diseases.
A major floor 31.5% below — a decisive break under it would weaken the trend.
The nearest floor, 4.8% below — buyers have tended to step in here.
The nearest ceiling, 37.6% above — a clean break opens room to run.
A major ceiling 88.0% above — clearing it would confirm fresh momentum.
Key KLRS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KLRS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.46 | Buy | $3.54 | Sell |
| MA 10 | $3.71 | Sell | $3.72 | Sell |
| MA 20 | $4.15 | Sell | $3.97 | Sell |
| MA 50 | $4.41 | Sell | $4.48 | Sell |
| MA 100 | $5.31 | Sell | $5.21 | Sell |
| MA 200 | $6.54 | Sell | $6.04 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.23 | Neutral |
| Stoch RSI (14) | 20.58 | Neutral |
| CCI (20) | -96.41 | Neutral |
| Williams %R (14) | -88.51 | Info |
| MACD (12,26,9) | -0.08 | Sell |
| ROC (12) | -27.18 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 11.49 | Buy |
| TRIX (15) | -0.66 | Sell |
| Awesome (5,34) | -0.79 | Sell |
| Ultimate (7,14,28) | 24.72 | Buy |
| Momentum (10) | -0.87 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 3.31 | Buy |
| ADX (14) | 22.29 | Sell |
| ATR (14) | 0.14 | Info |
The 30-day technical picture is Bearish, with an RSI of 30. The stock trades below key moving averages, with SMA50 at $4.55 and SMA200 at $6.60, indicating a weaker near-term trend. A defined near-term support is listed at $3.58 and resistance at $4.83, while the 30-day price action has traded within a range of $2.77 to $4.63.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.34 | $3.51 | $4.53 | 0% | Neutral | |
| $2.53 | $3.25 | $4.45 | -7% | Neutral | |
| $2.44 | $3.26 | $4.67 | -7% | Neutral | |
| $2.73 | $3.75 | $5.57 | +7% | Neutral | |
| $3.10 | $4.37 | $6.69 | +25% | Bullish | |
| $3.20 | $4.64 | $7.28 | +32% | Bullish | |
| $2.88 | $4.27 | $6.85 | +22% | Bullish | |
| $2.85 | $4.31 | $7.06 | +23% | Bullish | |
| $2.96 | $4.57 | $7.64 | +30% | Bullish | |
| $2.84 | $4.48 | $7.60 | +27% | Bullish | |
| $3.33 | $5.77 | $10.54 | +64% | Bullish | |
| $5.97 | $12.18 | $24.72 | +247% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.34 | $3.51 | $4.16 | +0.00% |
| September 2026 | $2.95 | $3.51 | $4.32 | +0.14% |
| October 2026 | $3.07 | $3.69 | $4.61 | +5.11% |
| November 2026 | $3.03 | $3.67 | $4.63 | -0.62% |
| December 2026 | $2.92 | $3.56 | $4.53 | -3.07% |
Click any year to see its month-by-month KLRS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, KLRS is projected to trade between $3.34 and $4.53, averaging $3.51 — a potential gain of 0% from today's $3.51. A consolidation phase looks the most probable path here.
Kalaris Therapeutics, Inc.'s 2027 outlook centres on $3.25, within a $2.53 to $4.45 range. That is -7% versus the projected 2026 average. That marks a -7% change versus current levels. Price action looks broadly range-bound.
By 2028, KLRS could reach as high as $4.67, with a base case around $3.26 and support toward $2.44 — roughly -7% from $3.51. A consolidation phase looks the most probable path here.
Expect KLRS to range from $2.73 to $5.57 through 2029. The $3.75 average target implies a +7% move from current prices. That is up +15% on the projected 2028 average. Price action looks broadly range-bound.
The KLRS price prediction for 2030 points to an average of $4.37 (low $3.10, high $6.69) — a potential gain of +25% on today's $3.51. Buyers look set to stay in control over this stretch.
In 2031, KLRS is projected to trade between $3.20 and $7.28, averaging $4.64 — a potential gain of +32% from today's $3.51. That is up +6% on the projected 2030 average. Momentum favours further upside here.
Kalaris Therapeutics, Inc.'s 2032 outlook centres on $4.27, within a $2.88 to $6.85 range. That is -8% versus the projected 2031 average. That marks a +22% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, KLRS could reach as high as $7.06, with a base case around $4.31 and support toward $2.85 — roughly +23% from $3.51. Momentum favours further upside here.
Expect KLRS to range from $2.96 to $7.64 through 2034. The $4.57 average target implies a +30% move from current prices. That is up +6% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The KLRS price prediction for 2035 points to an average of $4.48 (low $2.84, high $7.60) — a potential gain of +27% on today's $3.51. Momentum favours further upside here.
In 2040, KLRS is projected to trade between $3.33 and $10.54, averaging $5.77 — a potential gain of +64% from today's $3.51. That is up +29% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Kalaris Therapeutics, Inc.'s 2050 outlook centres on $12.18, within a $5.97 to $24.72 range. That is up +111% on the projected 2040 average. That marks a +247% change versus current levels. Momentum favours further upside here.
Investing $1,000 in KLRS today (≈ 284.900285 KLRS) could be worth
$3,471.21
+$2,471.21 (+247%) by 2050 · US Dollar
Based on the average projected KLRS price of $12.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KLRSwould be worth at today's price.
$1,000 invested in KLRS on Jul 31, 2025 (≈ 373.134319 KLRS) would be worth
$1,309.7
+$309.7 (+31.0%) today · 1.31× · US Dollar
Based on a KLRS entry price of $2.68 vs. today's $3.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.73 | $941.02 | -5.9% |
| 1 month ago | $4.53 | $774.83 | -22.5% |
| 3 months ago | $5.46 | $642.86 | -35.7% |
| 6 months ago | $9.11 | $385.29 | -61.5% |
| 1 year ago | $2.68 | $1,309.7 | +31.0% |
| All time (5.0y) ago | $464.6 | $7.55 | -99.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KLRS forecast.
Our base-case forecast reaches $7.00 around 2050.
Implied market cap at $7.00: $166.55M
The multi-year forecast shows a variable path with near-term pressure followed by longer-term upside. For 2026 the min is $3.58, the avg is $3.58, and the max is $4.65 with ROI 0; 2027 features a min of $2.47, an avg of $3.22, a max of $4.50 with ROI -10.1; 2028 shows a min of $2.26, an avg of $3.07, a max of $4.52 with ROI -14.1; 2029 presents a min of $2.49, an avg of $3.51, a max of $5.36 with ROI -2. By 2030 the min is $2.86, the avg is $4.16, the max is $6.57 with ROI 16.3.
The year 2031 shows a min of $2.94, an avg of $4.40, a max of $7.13 with ROI 22.8. In 2040 the min is $2.75, the avg is $5.10, the max is $9.75 with ROI 42.3, and in 2050 the min is $4.93, the avg is $10.95, the max is $23.43 with ROI 205.7. These figures point to a stronger upside in the later years, but indicate mixed momentum earlier and notable upside potential by the 2030s and 2040s, with a pronounced upside by 2050.
Tap a question to reveal the answer.
The 2030 forecast shows min $2.86, avg $4.16, max $6.57 with ROI 16.3 and sentiment NEUTRAL.
The forecast includes positive ROI in 2030 (16.3%), 2031 (22.8%), 2040 (42.3%), and 2050 (205.7%), but near-term years 2027 (-10.1) and 2028 (-14.1) show declines, with 2026 returning 0%.
By 2050 the max forecast is $23.43 and the avg is $10.95, so it could reach or exceed $10 by 2050. By 2040 the max is $9.75, so $10 is not expected by 2040 based on these figures.
For 2026 the avg is $3.58 with ROI 0; 2027 avg $3.22 ROI -10.1; 2028 avg $3.07 ROI -14.1; 2029 avg $3.51 ROI -2, indicating near-term softness before the path improves after 2029.
Current price is $3.58 and the market cap is $85.18M.
Kalaris Therapeutics, Inc. Community Discussion
0Share your Kalaris Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.